Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2015 02:30 ET | Source: Cantargia AB

Cantargia presents new data and development plan, non-small cell lung cancer and pancreatic cancer have been selected as primary indications for CAN04

Lund, 17 November 2015. Cantargia AB (“Cantargia”) will today be making a presentation at the “Sedermeradagen” in Stockholm. The company will be presenting a development plan for its CAN04 product...
October 08, 2015 02:30 ET | Source: Cantargia AB

Cantargia förstärker ledningsgruppen med Vice President Cancer Research

Cantargia AB (”Cantargia”) har utsett David Liberg till Vice President Cancer Research i Cantargia AB. Liberg har närmare tjugo års erfarenhet av forskning inom immunologi och tumörbiologi och...
October 08, 2015 02:30 ET | Source: Cantargia AB

Cantargia strengthens management with a Vice President Cancer Research

David Liberg has been appointed Vice President Cancer Research of Cantargia AB. Liberg has nearly twenty years of research experience within immunology and tumor biology and was graduated with a Ph.D....
October 06, 2015 03:50 ET | Source: Cantargia AB

Cantargia erhåller preliminärt godkännande av Europapatentverket för IL1RAP som målmolekyl för behandling av solida tumörer

Cantargia AB (”Cantargia”) har idag, den 6 oktober 2015, fått kännedom om att Europapatentverket (EPO) utfärdat ett så kallat ”Intention to Grant” för Cantargias patentansökan avseende IL1RAP som...
October 06, 2015 03:50 ET | Source: Cantargia AB

Cantargia obtains an “Intention to Grant” notice from the European Patent Office covering the IL1RAP target for the treatment of solid tumors

Cantargia AB (“Cantargia”) hereby announces that the European Patent Office (EPO) has issued an “Intention to Grant communication” for a patent application concerning IL1RAP as a target molecule for...
October 05, 2015 02:30 ET | Source: Cantargia AB

Cantargia AB: Europapatentverket utfärdar officiellt patentgodkännande

Cantargia AB (”Cantargia”) har fått sin patentansökan avseende IL1RAP som målmolekyl för antikroppsterapi och diagnostik av leukemi (patentnummer EP2467403) godkänd av Europapatentverket (EPO)....
October 05, 2015 02:30 ET | Source: Cantargia AB

Cantargia: Grant of patent by The European Patent Office (EPO)

Cantargia AB (“Cantargia”) hereby announce that the European Patent Office (EPO) has decided to grant the patent application concerning IL1RAP as a target molecule for antibody therapy and diagnostic...
August 25, 2015 02:30 ET | Source: Cantargia AB

Cantargias delårsrapport för första halvåret 2015 tillgänglig

Lund, Sverige 25 augusti, 2015 - Cantargia AB:s delårsrapport för första halvåret 2015 finns nu tillgänglig på bolagets hemsida (www.cantargia.com). Nedan presenteras utdrag ur rapporten. Väsentliga...
August 25, 2015 02:30 ET | Source: Cantargia AB

Cantargia Interim Report for the period 1 Jan 2015 – 30 June 2015 available

Lund, Sweden 25 August 2015 – Cantargia AB Interim Report for the second quarter 2015 is now available on the company web-site (www.cantargia.com). An extract from the report is presented...
August 11, 2015 02:30 ET | Source: Cantargia AB

Data kring Cantargias antikroppar i modeller av leukemi publicerade i internationell vetenskaplig tidskrift

Lund, Sverige 11 augusti, 2015 - Cantargia AB (CANTA:SS) meddelar idag att en vetenskaplig artikel kring användandet av Cantargias antikroppar i prekliniska modeller av akut myeloisk leukemi (AML)...